Expert NetworkExpert InterviewCALT

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan

Executed on:Jun 13, 2023 4:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: UPENN
  • Associate Professor of Clinical Medicine and the Clinical Director, Glomerular Diseases Program at University of Pennsylvania.
  • Currently manages 100 patients with IgAN, 1000 patients with CKD, and 15 patients with C3 glomerulopathy.
  • Research focuses on Glomerular diseases, Onconephrology, and kidney biopsy.

Interview Goal

This call will focus on the FDA approval of Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and the results from the phase 3 ALIGN study regarding Chinook's Atrasentan. This call will also compare and contrast all three medications potential for treatment of IgA Nephropathy.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.